EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives

Samuel Chima Ugbaja, Ata Thabo Mokoena, Aganze Gloire-Aimé Mushebenge iD, Hezekiel M Kumalo, Mlungisi Ngcobo, Nceba Gqaleni iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Samuel Chima Ugbaja und 5 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Traditional Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban 4000, South Africa. Hauptthemen laut MEDLINE: Drug Repositioning, Hepatitis B virus, Hepatitis B, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B is one of the killer communicable diseases, with a global estimation of 1.1 million deaths resulting from liver diseases annually. The search for HBV therapeutics has resulted in repurposing the existing antiretrovirals (ARVs) for HBV treatment, considering their shared common replication mechanisms. This review is aimed at evaluating the potencies of some of the repurposed ARVs used for HBV treatment, analyzing the common mechanisms of viral replications in HBV and HIV, and investigating the potentials of traditional medicines as an alternative treatment for HBV patients. The topical keywords drug repurposing, drug repositioning, antiretrovirals, hepatitis B treatment, HBV, natural products, traditional medicines, title, and abstract were searched in PubMed, Web of Science, and Google Scholar. The advanced search included the five years, 2019–2024. The search result was filtered from 377 to 110 relevant articles. The evaluation reveals that CD4+ T cells are targeted by HIV, while HBV targets the liver with its associated diseases (cirrhosis and hepatocellular carcinoma (HCC)). Furthermore, treatments with the available repurposed ARVs only prevent or slow down the progression to cirrhosis, reduce the HCC incidence, and can improve the quality of life and increase life expectancy; however, they are not curative for HBV. Traditional medicines/natural product extracts or their phytochemicals exert anti-HBV effects through different mechanisms. Traditional medicines exert improved therapeutic effects when combined properly. The investigation further reveals that consideration of an in silico approach in HBV therapeutics might not only streamline drug development but also contribute to a deeper understanding of viral pathogenesis. Therefore, we recommend the integration of computational drug design methods with traditional medicine and natural product screening for discovering new bioactive HBV drug candidates

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningHepatitis B virusHepatitis BAntiviral AgentsMedicine, TraditionalAnti-Retroviral AgentsHumansVirus Replication

Stichwörter der Autor:innen

ARVHBV therapyHIVcomputational drug designhepatocellular carcinomarepurposingtraditional medicines

Substanzen

Antiviral AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Discipline of Traditional Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban 4000, South Africa.
  • Africa Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4000, South Africa.
  • Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.
  • Faculty of Pharmaceutical Sciences, University of Lubumbashi, Lubumbashi 1825, Democratic Republic of the Congo.
  • Drug Research and Innovation Unit, Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban 4000, South Africa.

ORCID-Profile: Aganze Gloire-Aimé Mushebenge, Nceba Gqaleni

Zitieren

APA

Ugbaja, S. C., Mokoena, A. T., Mushebenge, A. G., Kumalo, H. M., Ngcobo, M., & Gqaleni, N. (2025). Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041523

Vancouver

Ugbaja SC, Mokoena AT, Mushebenge AG, Kumalo HM, Ngcobo M, Gqaleni N. Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041523

BibTeX
@article{Ugbaja2025,
  author = {Ugbaja, Samuel Chima and Mokoena, Ata Thabo and Mushebenge, Aganze Gloire-Aimé and Kumalo, Hezekiel M and Ngcobo, Mlungisi and Gqaleni, Nceba},
  title = {Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041523}
}
Kostenlos starten →